upgrad overweight
 js defens legal liabil appear
reflect pharma segment acceler
busi balanc factor
appreci significantli discount sotp valu
rel multipl creat attract buy opportun
look defens divers three-way street april
note portfolio increasingli weight pharma would drive multipl
compress sinc valuat discount expand
nearli widest decad pictur evolv multipl
regulatori action aim control pharma price reflect
pharma growth like acceler histor lift
multipl portfolio balanc consum stabil
medic devic diagnost md busi come six
consecut quarter momentum improv structur mani concern
address consid stock appear price
significantli legal liabil probability-weight analysi suggest
see defens return result multipl expans
out-performance
legal liabil risk/reward look favor opioid talc litig
domin debat rel valuat multipl vs move
peak trough less year adjust pharma
multipl contract market may price pre-tax legal
liabil npv stock price impact analysi suggest even
bear case scenario legal liabil npv impact would
per share market significantli over-estim aggreg legal
liabil view see current valuat discount vs
 unwarr averag base case bull case
estim legal liabil respect per share impact
pleas see legal liabil bear reflect
deep-div analysi legal liabil calcul
pharma growth stock highli correl bottom-
analysi leav us confid acceler driver includ
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
discount outflow
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
exhibit summari estim liabil scenario
eas headwind blockbust indic expans pipelin
pharma headwind eas year drive
growth trend carri anniversari zytiga see
tailwind blockbust franchis stelara darzalex imbruvica
sale like outperform street drive point pharma
growth pipelin driver tremfya spravato balversa erleada
drive bp driven share gain indic expans rais
pharma outlook street drive growth
see upsid number note everi point pharma upsid
bp corpor pleas see pharma acceler drive multipl
balanc profil emerg ceo gorski reli heavili
pharma earli tenur catch pharma price headwind miss devic
innov view see exhibit capit deploy analysi sinc
compani taken activ approach portfolio manag
lifescan asp etc cut cost agreement driven md growth
flat trough growth even pharma acceler progress evid
organ growth project come pharma vs
averag sinc md growth continu show momentum
model md growth drive bp corpor consum
perform line market net model impli
corpor organ growth vs pleas see
balanc growth portfolio fare sum-of-the-part addit detail
sotp valu meaning higher upgrad overweight ntm price-to-earnings
valuat trade discount nearli widest
discount pt wider averag discount
sotp analysi yield price target upsid despit
sever pocket conservat includ segment margin expans
modestli conserv segment multipl see exhibit upgrad
overweight view legal liabil reflect valuat
pharma drive acceler balanc approach
portfolio risk call includ legal liabil greater
bear case remain overhang slower ramp pharma pipelin
product deceler consumer/md franchis rais price
target vs prior base ep discount vs
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig ip
prosecut talent trial proceed locat juri composit judg
examin composit investor contact legal advisor issu
law relat subject matter materi
price target base multipl
base case ep support sotp analysi assum
trade mid-single-digit discount given growth
acceler pharma improv fundament
consumer/md balanc litig overhang
bull case ep
bull case ep
pharma organ growth acceler high-singl digit md
consum demonstr momentum oper leverag gener lead
sustain dd ep growth make progress litig process
overhang gradual remov share aggreg legal liabil
 trade valuat in-lin slight premium
base ep sotp-support
base ep sotp-support
blockbust franchis pipelin launch contribut pharma
acceler drive multipl margin higher md continu
modestli acceler consum stabil in-lin market
growth aggreg legal liabil valuat disconnect vs
narrow progress toward legal settlement made
bear ep
bear ep
competit threat biosimilar eros continu lead lsd/msd growth
pharma md consum deceler y/i segment revers cours
 leverag limit driven incom gap neg newsflow
opioid talc risperd continu weigh share aggreg legal
liabil total trade discount
litig liabil
reflect share view creat
meaning valuat disconnect vs
pharma-driven acceler pois
drive multipl higher led
blockbust franchis pipelin launch
momentum md consum
segment drive balanc
growth profil less reliant
progress toward litig settlement
drive narrow discount
blockbust pipeline-driven launch
drive pharma acceler point
increment pharma growth drive bp
md consum segment
demonstr sign improv
segment pois acceler
progress on-going litig process
particularli opioid talc
trial read-out
risk achiev price
greater anticip
pharma pipelin unabl off-set
biosimilar competit risk
turnaround consum md fail
materi occur slowli
legal liabil domin invest debat past month
rel valuat multipl vs move decemb
trough mid-novemb stock sold period
analysi impli even calcul bear case scenario legal liabil
impli stock price impact base case estim legal liabil
stock price impact compar sell-off discuss bull case
estim legal liabil stock price impact amidst fundament
improv see suggest liabil price
stock discuss signific invest debat revolv around
opioid talc risperd dive
prior analysi estim base case liabil aggreg frame potenti
opioid liabil exposur estim potenti liabil exposur on-going
opioid litig primari invest debat past month
analysi yield base case liabil base manufactur
market durages nucynta sale
multipli liabil sourc compani api suppli bull case
estim liabil base multipli bear case scenario
involv liabil level market product well
proportion liabil compani api market share full
detail origin analysi
recent develop point global settlement octob wsj
bloomberg report cardin teva
propos potenti settlement resolv opioid-rel claim see
involv payment admiss liabil notabl week
later issu see state taken retroact gaap
charg reflect matter although agreement/propos subject
agre upon oppos parti oklahoma judg thad balkman
acknowledg calcul error made damag rule involv
overstat correct reflect judgement file late
novemb judg balkman modifi rule payment see
consid sever factor narrow scenario assumpt
liabil rang base case unchang discuss
pleas see recent discuss opioid litig detail
us healthcar north america thought propos opioid settlement oct
us healthcar list plan opioid trial dec
upcom opioid catalyst includ confirm detail structur
propos global settlement would pay oklahoma appeal process
purdu bankruptci court updat addit state opioid case see
scenario analysi base recent develop case progress
narrow estim opioid liabil rang base case assumpt
unchang base global estim lack clariti whether
incorpor claimant citi region counti muni etc includ
oklahoma rule base recent disclosur teva see see liabil
amount paid period least year includ
base case assumpt liabil year per year
discount back present valu impli tax-adjust impact share
price dcf-basi note sinc peak dec octob sold-
vs although admittedli attribut varieti
factor beyond opioid includ talc risperd discuss analysi
implic detail bull case see floor given
disclosur retroact charg taken becom clear take step
resolv litig bear case lower estim given
settlement discuss on-going settlement discuss
greater purdu propos difficult plausibl see liabil
greater purdu believ plaintiff api argument appear
becom less strong given recent settlement discuss recent rumor
settlement number impli exposur relat brand vs brand api note
bear case analysi origin involv brand api exposur
current state talc litig talc becam larger part debat last summer
missouri juri order pay compensatori damag
punit damag talc case announc plan appeal given prior verdict
court revers stock still declin follow day
time outstand talc case neg press continu
decemb reuter articl claim knew asbesto contamin
babi powder decad share fell erod market cap outstand
case climb total outstand case number climb
feder case consolid mdl new jersey
repres case corpor expert convers suggest
outstand case relat ovarian cancer relat mesothelioma
mdl parti move exclud expert known daubert motion
discuss
pleas see recent discuss talc litig detail
johnson johnson talc reaction flaw scienc dec
johnson johnson unansw question talc oct
johnson johnson deeper dive talc test still posit step oct
recent disclosur impact view mid-octob talc litig
brought back debat announc voluntari recal singl lot
babi powder respons fda test indic small presenc asbesto see
 stock fell concern regard broader contamin may lead
meaning greater liabil week later independ test conclud
presenc asbesto fda stood lab result see clear
increment posit clear continu comprehens
investig test test conduct two third parti lab conclud
presenc asbesto addit investig reveal test
protocol ama deviat standard practic ama execut full
asbesto confirm requir lab test method see full detail
compani claim probabl caus fda report result
either test sampl contamin and/or analyst error ama lab next day
fda reiter stood studi result given conclud investig
on-going back forth fda statement see on-going test
like conclud rel newsflow subsid
thought daubert trial mention plaintiff move
exclud certain oppos parti expert mdl testimoni process expert
evalu prior trial known daubert motion review
nj mdl judg judg freda wolfson hear began juli took place
period final brief submit court septemb
await judg wolfson decis exact time decis unclear
expert convers suggest judg like take time review wit
wit decis year-end earli reason expect given
opaqu litig process difficult hypothes exact outcom
daubert hear said daubert trial critic analysi
view potenti sourc upsid even worst case scenario judg
wolfson allow plaintiff wit testifi defens stay
see risk-reward favor come daubert decis
expect trial materi driver either direct broader litig
upcom talc catalyst includ potenti updat talc fda test although
unlik nj daubert hear decis like missouri
scenario analysi base case take current outstand talc case disclos
sec file separ ovarian/mesothelioma dilig suggest
averag mesothelioma settlement rang use
midpoint base case ovarian admittedli challeng handicap given lack
settlement preced limit scienc support link ovarian
cancer/asbesto assum averag ovarian settlement
mesothelioma net arriv base case settlement bull/bear
case skew includ /- chang case count assum abl resolv
portion case liabil bull case assum ramp case count
bear case mesothelioma settlement assumpt bracket
rang /- chang ovarian arriv bull
bear case liabil respect note outcom daubert hear like
provid somewhat futur indic toward mdl outcom although critic
outcom trial although caution much analysi base estim
date pleas see exhibit scenario analysi correspond build talc
liabil exhibit probability-weight assumpt
histori risperd litig initi approv risperd antipsychot
use treat symptom schizophrenia teenag adult mid
late variou gynecomastia men grow breast lawsuit aros
risperd risperd case outstand recent
file state declin worth note abl
resolve/settl case littl financi disclosur case
compani settl dilig suggest averag settlement/compensatori
damag howev recent octob philadelphia juri order
pay punit damag risperd case sent stock
equiti valu see publicli state award grossli
disproportion initi compensatori award case compani
confid overturn also cite plan appeal
investor like gravit toward vioxx settlement bear case proxi merck
litig process relat vioxx see natur proxi investor may look
toward analyz risperd exposur merck undergon sever key
settlement throughout vioxx litig histori howev notabl
settl case see best proxi impli
per case assign preced risperd outstand case arriv
total liabil note approach like grossli overestim propos
liabil given recent abil settle/resolv case littl financi
disclosur convers suggest reserv capit
litig process speak level confid decis
overturn well abil resolve/settl remain case without meaning
impact cash flow howev vioxx like preced investor gravit toward
given meaning reduct case count recent year limit financi
disclosur assum bear case scenario assign low probabl
upcom risperd catalyst includ appeal process regard recent
punit judgement expect reduced/overturn see
scenario analysi state investor like gravit toward vioxx potenti
proxi risperd liabil see fair base case scenario howev assign
low probabl given settled/resolv case past year
limit financi disclosure/cash outlay suggest case preced
stronger base case assum per case settlement vs vioxx
arriv aggreg bull case assum per case impli
aggreg see bull/bas case like due preced
track record litig process howev given recent punit damag
award risperd come back invest debat fear surround
signific settlement sent stock note even settlement
scenario year impli impact dcf-basi share price
impact greater reaction post announc
net see bear case legal liabil price outlin
determin probability-weight aggreg legal liabil across opioid talc
risperd across year see exhibit tax-adjust discount
cash outflow back conserv rate impli aggreg
discount cash flow impact stock price adjust pharma
multipl contract market may price legal liabil
npv stock price impact see signific over-estim even
bear case scenario aggreg legal liabil year use
methodolog impli share price impact see exhibit legal liabil
scenario analysi conclud even bear-cas scenario base detail
framework legal liabil becom price share
current valuat disconnect overdon discuss
exhibit summari liabil scenario
exhibit legal liabil scenario impli stock price impact
discount outflow
note assum statutori tax rate compar purpos discount rate dilut share outstand
discount outflow
discount outflow
exhibit probability-weight legal liabil impli stock price impact
discount outflow
note assum statutori tax rate compar purpos discount rate dilut share outstand
pharma acceler drive multipl
pharma organ growth highli correl stock perform total
revenu surpris pharma segment highli correl stock
perform see exhibit pharma segment outperform peer
averag point growth past year discuss
expect segment acceler like drive stock
multipl higher manag background may play role success ceo
gorski year profession experi pharma
novarti contrast head md year prior ascens
ceo role argu execut well pharma segment
grown averag versu industri growth rate
exhibit stock perform correl pharma organ growth
acceler like see multipl driver lead pharma
acceler mainli driven eas headwind indic expans
blockbust franchis uptak new product launch expect
least new blockbust approv file well
line extens current franchis potenti
although sever factor contribut alreadi
seen spravato balversa includ blockbust potenti admittedli
time pharma analyst day expect pharma growth year
howev model indic growth like mainli due foreseen
headwind mitig bp increment natur creat
challeng comp said discuss
confid abil acceler segment growth impli
point corpor growth deliv point pharma upsid vs model
would drive increment bp corpor growth
swing factor see broad base strength pharma portfolio
follow year modest headwind certain compon portfolio
drive meaning contribut
blockbust stelara darzalex imbruvica repres aggreg
sale grown annual sinc launch variou
indic expans plan blockbust notabl uc
pediatr psoriasi lupu stelara subcutan formul maia
darzalex mcl imbruvica well continu share gain frontlin
model growth three product drive point pharma growth
discuss potenti product detail
recent launch product expect uptak recent launch product
notabl tremfya spravato balversa erleada key driver
acceler drive bp growth model tremfya sale grow
next year driven market share gain expans psoriat arthriti
although sale disclos yet see spravato
opportun mdd center current certifi balversa
emphas fgfr use varieti cancer engag
sever studi lung esophagael tissu agnost expand clinic
program recent commentari suggest believ erleada peak sale
may becom larger zytiga overtim expect robust uptak
sale disclos model sale erleada drive
bp growth pleas see detail product
carry-ov headwind head forecast
foreseen pharma headwind relat gener biosimilar impact us zytiga
us remicad velcad procrit tracleer throughout year headwind
mitig varieti reason includ delay competitor launch
discount maintain share gener less expect eros
manag forecast headwind thu impli least
carri bp pharma growth creat
upcom catalyst watch mention plan meaning line
extens filings/approv come quarter key product mani
could potenti discuss catalyst pharma analyst
day note headwind side result zytiga remicad particularli
lead indic declin trajectori current model
declin remicad declin us zytiga bp
pharma growth discuss pharma analyst day preview face
key loss exclus headwind eu zytiga us stelara see
exhibit forecast degrad product sale closer
time-frame although industri dynam step closer
polit elect regulatori updat propos regard drug price may ensu
volatil space whole
exhibit pharma loss exclus period
balanc growth portfolio fare sum-of-the-part
over-reli pharma weigh multipl discuss divers
three-way street sector continu face seri structur
industri pressur like weigh multipl compani revenu
exposur pharma grown see exhibit
 organ growth sinc driven pharma see
exhibit place over-reli segment compar devices/consum
busi grown market nearli decad
strateg action support balanc profil ceo gorski
deploy toward two-third dedic pharma
although admittedli actelion howev sinc capit
strateg activ focus device/consum space seen exhibit
discuss discuss support activ
fundament improv segment creat balanc growth profil
compar recent year model impli organ growth would
driven pharma compar averag sinc
 deploy toward devic sinc
notabl acquir auri see deal
smaller mani like disclos note made sever privat
invest space increas exposur grail carbon inivata etc
consum compani deploy sinc recent notabl
acquisit includ dr ci labo zarbe
divestitur particularli md undertaken signific strateg activ
optim portfolio divest lower growth non-leadership asset
improv focu drive wamgr higher exampl compani divest
diabet busi averag bp drag cc growth sinc
recent sold asp busi
improv fundament warrant higher segment multipl discuss
pharma great detail expect busi acceler model
growth segment pharma peer thu warrant
premium multipl devic segment grown averag sinc
howev growth gradual improv
momentum improv averag bp per quarter md organ growth
strongest absolut quarter sinc strongest momentum
improv expect within rang see detail although
busi improv still forecast grow peer segment
see slight discount appropri consum expect growth in-
line market rang end-market improv portfolio
optim initi anniversari assign more-in line multipl consum
segment exhibit compar analysi
note includ announc strateg invest
note includ announc strateg invest
sum-of-the-part analysi yield premium trade level sum-of-the-part
sotp analysi impli price target upsid current note
analysi includ varieti conserv assumpt assum segment
margin expans modestli conserv segment multipl despit
continu believ full split compani unlik given manag
commentari howev state previous believ increas exposur devic
would bode well valuat multipl given fundament improv
across sector see exhibit md segment forecast acceler
grow in-lin end-market devic trade
premium vs discount
modestli conserv multipl embed sotp analysi state
sotp analysi forecast segment margin expans despit continu
focu manag improv segment profit particularli consum
segment multipl assum base compar analysi see
exhibit risk-adjust appropri consum appli
multipl maintain low growth low gross-margin
commod sensit busi assum consum segment trade
warrant premium multipl vs peer growth track vs
peer like acceler appli multipl pharma
modestli peer devic see zimmer biomet
floor valuat given structur lower growth profil see segment
warrant bd/medtron multipl assign ebitda multipl
select peer see appropri risk-adjust given segment
grown market sever year note may prove conserv
segment show sign improv market multipl expand
devic given broader durabl growth see exhibit
note estim consensu estim sourc thomson reuter
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
valuat discount nearli widest ntm price-to-earnings valuat
trade discount nearli widest discount
pt wider averag discount
rel valuat vs index hover mid-single-digit premium/discount rang
peak decemb discount widen juli
doj announc investig talc dd discount ever sinc trough
repres point swing less year understood case
 trade mid-single-digit discount given litig overhang outsiz
exposur pharma experienc structur challeng sever
year see current valuat disconnect overdon given litig overhang
price discuss fundament improv across segment see
pharma acceler like next year see mid-singl digit
discount appropri vs rais updat price target
exhibit rel ntm price-to-earnings ratio
yield like remain peer even bear case liabil scenario
yield compar favor consum devic peer in-lin
pharma peer discuss probability-weight base case
scenario total liabil year per year would
bp impact yield given model impli gener
gradual improv thereaft even bear case scenario total liabil
year per year would impact bp see exhibit
sensit analysi yield impact pro-forma bear case yield
would still in-lin select peer net although face valu liabil headlin
risk clear neg sentiment like stock proven
past month step back run number impli modest impact
compani profil
 rel under-own healthcar stock exhibit display rel
ownership weight amongst variou investor group vs russel index
weight time clear mani investor group rel
underweight signific period time howev analysi data across
healthcar conclud rel underweight stock amongst
healthcar stock meaning margin particularli seen appar activ
mutual fund rel weight vs underweight
hedg fund rel weight current among
investor group vs second underweight
note data
litig uncertainti extens analysi dilig led us
conclus estim liabil scenario major litig opioid talc
risperd howev challeng predict certainti actual liabil
outcom given opaqu litig process although preced would
impli paydown structur sever year possibl although unlik
view liabil scenario could involv meaning up-front payment
exampl said run math absent unpreced liabil scenario
exampl respons materi proport total opioid
liabil see liabil scenario would materi alter compani
profil subject variou litig process span
sever year any/al case drag extend period time
rather settle/resolv like overhang remain share given lack
clariti
headlin risk seen recent risperd judgment see stock
subject signific headlin risk risperd exampl earli octob stock
declin follow day howev discuss judgment like
overturned/reduc given preced view stock perform
signific over-react unlik subsid move forward variou
litig process resolv clariti path forward
liabil figur howev investor take time run math look
preced one make adequ judgment regard financi impact in-turn
appropri share price impact
fundament improv pharma acceler part thesi
predic fundament improv across board creat balanc
growth profil pharma clear growth engin past
decad drive averag total corpor growth profil model
impli pharma growth drive point corpor growth
gener biosimilar competit intensifi and/or new product uptak mute
becom less like pharma acceler consum md grown
market past sever year despit recent improv seen
segment thesi base growth potenti reach in-lin market
segment drive multipl expans
 headwind creat mute ep growth next year discuss js asp
divestitur gain year creat point ep growth headwind
becom understand investor concern next year given greater level
margin expans requir off-set gap follow earn
manag eas concern point incom number
creat point ep headwind note similar gap dynam seen
 anniversari greater incom headwind
compani leverag sg off-set follow year compani
deliv bp margin expans respect rel
expect bp abl leverag cost next year fill
gap unlik compani abl deliv earn growth in-lin greater
revenu
good sold
debt current liabil
net chg oper asset liab
oper
proce dispos asset
sale invest
invest activ
chang current debt
chang long-term debt
chang capit stock
financ activ
begin period
end period
